Mediators of First- Versus Second-generation Antipsychotic-related Mortality in Older Adults

Epidemiology

Volumn 26, Issue 5, 2015, Pages 700-709

  Jackson, John W ^a,b   VanDerWeele, Tyler J ^b   Blacker, Deborah ^b,c   Schneeweiss, Sebastian ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; FLUPHENAZINE; HALOPERIDOL; LOXAPINE; MESORIDAZINE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PIMOZIDE; PROMAZINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; TRIFLUPROMAZINE; ZIPRASIDONE;

AGED; ARTICLE; ATTRIBUTABLE RISK; BACTERIAL INFECTION; BILLING AND CLAIMS; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; FEMALE; HEART INFARCTION; HEART VENTRICLE ARRHYTHMIA; HIP FRACTURE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; MORTALITY; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; UNITED STATES; VENOUS THROMBOEMBOLISM; AGE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; COMPARATIVE STUDY; EPIDEMIOLOGY; FOLLOW UP; NEW JERSEY; PENNSYLVANIA; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; EFFECT MODIFIER, EPIDEMIOLOGIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MALE; MEDICARE; NEW JERSEY; PENNSYLVANIA; PNEUMONIA; RETROSPECTIVE STUDIES; RISK FACTORS; UNITED STATES;

EID: 84940030388     PISSN: 10443983     EISSN: 15315487     Source Type: Journal    
DOI: 10.1097/EDE.0000000000000321     Document Type: Article

References (41)

1. Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS. Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf. 2011;20:177-184.
2. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934-1943.
3. Jackson JW, Schneeweiss S, VanderWeele TJ, Blacker D. Quantifying the role of adverse events in the mortality difference between first and second-generation antipsychotics in older adults: systematic review and meta-synthesis. PLoS One. 2014;9:e105376.
4. FDA Issues Public Health Advisory for Antipsychotic Drugs used for Treatment of Behavioral Disorders in Elderly Patients. FDA Talk Paper, 2005.
5. US Food and Drug Administration. Public Health Advisory: Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafety InformationforPatientsandProviders/DrugSafetyInformationforHeathcare Professionals/PublicHealthAdvisories/ucm053171.htm. Accessed August 6, 2013.
6. Setoguchi S, Wang PS, Alan Brookhart M, Canning CF, Kaci L, Schneeweiss S. Potential causes of higher mortality in elderly users of conventional and atypical antipsychotic medications. J Am Geriatr Soc. 2008;56:1644-1650.
7. Smith Sehdev AE, Hutchins GM. Problems with proper completion and accuracy of the cause-of-death statement. Arch Intern Med. 2001;161:277-284.
8. Roulson J, Benbow EW, Hasleton PS. Discrepancies between clinical and autopsy diagnosis and the value of post mortem histology; a meta-analysis and review. Histopathology. 2005;47:551-559.
9. Pratt N, Roughead EE, Salter A, Ryan P. Choice of observational study design impacts on measurement of antipsychotic risks in the elderly: a systematic review. BMC Med Res Methodol. 2012;12:72.
10. VanderWeele TJ. Bias formulas for sensitivity analysis for direct and indirect effects. Epidemiology. 2010;21:540-551.
11. VanderWeele TJ, Chiba Y. Sensitivity analysis for direct and indirect effects in the presence of exposure-induced mediator-outcome confounders. Epidemiol Biostat Public Health. 2014;11:e9027.
12. VanderWeele TJ, Vansteelandt S. Mediation analysis with multiple mediators. Epidemiol Method. 2014;2:95-115.
13. Social Security Death Master File. Available at: http://www.ssdmf.com. Accessed December 1, 2012.
14. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003;64:663-667.
15. Jackson JW. Does it look like a sequentially randomized trial? Covariate balance in studies of time-varying and other joint-exposures. Presented at: Society for Epidemiologic Research SERdigital 2014 Conference; November 6, 2014. Available at: https://epiresearch.org/ser50/serdigital/. Accessed January 21, 2015.
16. Vansteelandt S, Keiding N. Invited commentary: G-computation-lost in translation? Am J Epidemiol. 2011;173:739-742.
17. Valeri L, Vanderweele TJ. Mediation analysis allowing for exposuremediator interactions and causal interpretation: theoretical assumptions and implementation with SAS and SPSS macros. Psychol Methods. 2013;18:137-150.
18. Vanderweele TJ, Vansteelandt S. Odds ratios for mediation analysis for a dichotomous outcome. Am J Epidemiol. 2010;172:1339-1348.
19. Baron JA, Lu-Yao G, Barrett J, McLerran D, Fisher ES. Internal validation of Medicare claims data. Epidemiology. 1994;5:541-544.
20. McDonald KM, Hlatky MA, Saynina O, Geppert J, Garber AM, McClellan MB. Trends in hospital treatment of ventricular arrhythmias among Medicare beneficiaries, 1985 to 1995. Am Heart J. 2002;144:413-421.
21. Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J. 2004;148:99-104.
22. Lee DS, Donovan L, Austin PC, et al. Comparison of coding of heart failure and comorbidities in administrative and clinical data for use in outcomes research. Med Care. 2005;43:182-188.
23. Aronsky D, Haug PJ, Lagor C, Dean NC. Accuracy of administrative data for identifying patients with pneumonia. Am J Med Qual. 2005;20:319-328.
24. White RH, Garcia M, Sadeghi B, et al. Evaluation of the predictive value of ICD-9-CM coded administrative data for venous thromboembolism in the United States. Thromb Res. 2010;126:61-67.
25. Andrade SE, Harrold LR, Tjia J, et al. A systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative data. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):100-128.
26. Schneeweiss S, Robicsek A, Scranton R, Zuckerman D, Solomon DH. Veteran's affairs hospital discharge databases coded serious bacterial infections accurately. J Clin Epidemiol. 2007;60:397-409.
27. Strom BL. Data validity issues in using claims data. Pharmacoepidemiol Drug Saf. 2001;10:389-392.
28. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58:323-337.
29. Ogburn EL, VanderWeele TJ. Analytic results on the bias due to nondifferential misclassification of a binary mediator. Am J Epidemiol. 2012;176:555-561.
30. Valeri L, Vanderweele TJ. The estimation of direct and indirect causal effects in the presence of misclassified binary mediator. Biostatistics. 2014;15:498-512.
31. Carroll RJ, Ruppert D, Stefanski LA, Crainiceanu CM. Measurement Error in Nonlinear Models: A Modern Perspective. 2nd ed. Boca Raton, FL: Chapman and Hall/CRC; 2006.
32. Lyles RH, Lin J. Sensitivity analysis for misclassification in logistic regression via likelihood methods and predictive value weighting. Stat Med. 2010;29:2297-2309.
33. Wang PS, Schneeweiss S, Setoguchi S, et al. Ventricular arrhythmias and cerebrovascular events in the elderly using conventional and atypical antipsychotic medications. J Clin Psychopharmacol. 2007;27:707-710.
34. Huybrechts KF, Schneeweiss S, Gerhard T, et al. Comparative safety of antipsychotic medications in nursing home residents. J Am Geriatr Soc. 2012;60:420-429.
35. Huybrechts KF, Rothman KJ, Silliman RA, Brookhart MA, Schneeweiss S. Risk of death and hospital admission for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes. CMAJ. 2011;183:E411-E419.
36. Finkel S, Kozma C, Long S, et al. Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics. Int Psychogeriatr. 2005;17:617-629.
37. Salzman C. Clinical Geriatric Psychopharmacology. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005.
38. Sacchetti E, Trifirò G, Caputi A, et al. Risk of stroke with typical and atypical anti-psychotics: a retrospective cohort study including unexposed subjects. J Psychopharmacol. 2008;22:39-46.
39. Chan MC, Chong CS, Wu AY, et al. Antipsychotics and risk of cerebrovascular events in treatment of behavioural and psychological symptoms of dementia in Hong Kong: a hospital-based, retrospective, cohort study. Int J Geriatr Psychiatry. 2010;25:362-370.
40. Jackson JW, VanderWeele TJ, Viswanathan A, Blacker D, Schneeweiss S. The explanatory role of stroke as a mediator of the mortality difference between older adults who initiate first vs. second generation antipsychotics. Am J Epidemiol 2014;180:847-852.
41. Mitchell E, Schliep K, Schisterman E. Trucation Investigations: Using Sensitivity Analyses to Uncover Potential Sources of Bias Due to Truncation in Time to Event Studies. Presented at: Society for Epidemiologic Research SERdigital 2014 Conference; November 6, 2014. Available at: https://epiresearch.org/ser50/serdigital/. Accessed January 21, 2015.